Icu Medical Inc (ICUI) valuation

NASDAQ · Health Care

$163.78 -2.89% Close Oct 30, 2026 Live

Icu Medical P/E ratio history

Icu Medical trades at 137.6 times its earnings over the last twelve months and 17.8 times the earnings analysts expect over the next twelve. At its last 6 fiscal year ends its P/E ranged from 39.8 (year to Dec 2019) to 174.0 (year to Dec 2018), with a median of 51.6.

P/E at fiscal year endForward P/E at fiscal year end
50100150
201620172018201920202021
At each fiscal year end. Price is our close on that day; EPS is the fiscal year's diluted earnings per share, both in today's shares.
Fiscal year endedPriceEPSP/EForward P/E
Dec 31, 2025$142.67$0.03n/m18.1
Dec 31, 2024$155.17-$4.83n/m23.2
Dec 31, 2023$99.74-$1.23n/m18.1
Dec 31, 2022$157.48-$3.11n/m—
Dec 31, 2021$237.34$4.7450.1—
Dec 31, 2020$214.49$4.0353.2—
Dec 31, 2019$187.12$4.7039.8—
Dec 31, 2018$229.63$1.32174.0—
Dec 31, 2017$216.00$3.3364.9—
Dec 31, 2016$147.35$3.6939.9—

n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.

Icu Medical valuation against its peers

At the close on Oct 30, 2026.
CompanyMarket valueP/EForward P/EPrice / sales
Icu MedicalICUI $4.09B 137.617.81.9
IrhythmIRTC $4.05B —137.34.9
CorvelCRVL $4.17B 36.5—4.2
Indivior PharmaceuticalsINDV $4.17B 9.97.93.0
Arcutis BiotherapeuticsARQT $4.01B 145.836.48.6
LiquidiaLQDA $4.01B 32.221.48.9
Edgewise TherapeuticsEWTX $4.18B ———
VeracyteVCYT $3.99B 35.726.07.1
Definium TherapeuticsDFTX $3.96B ———
Peer median35.726.06.0

Reading these multiples

The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.

See also: ICUI financials · ICUI returns

No forecast, no recommendation. This page describes Icu Medical Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.